These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34150724)

  • 1. Combined Effects of Exercise and Denosumab Treatment on Local Failure in Post-menopausal Osteoporosis-Insights from Bone Remodelling Simulations Accounting for Mineralisation and Damage.
    Martínez-Reina J; Calvo-Gallego JL; Pivonka P
    Front Bioeng Biotechnol; 2021; 9():635056. PubMed ID: 34150724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Strategies for Safe Drug Discontinuation and Transition of Denosumab Treatment in PMO-Insights From a Mechanistic PK/PD Model of Bone Turnover.
    Martínez-Reina J; Calvo-Gallego JL; Martin M; Pivonka P
    Front Bioeng Biotechnol; 2022; 10():886579. PubMed ID: 35966026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of long-term treatment of denosumab on bone mineral density: insights from an in-silico model of bone mineralization.
    Martínez-Reina J; Pivonka P
    Bone; 2019 Aug; 125():87-95. PubMed ID: 31055117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are drug holidays a safe option in treatment of osteoporosis? - Insights from an in silico mechanistic PK-PD model of denosumab treatment of postmenopausal osteoporosis.
    Martínez-Reina J; Calvo-Gallego JL; Pivonka P
    J Mech Behav Biomed Mater; 2021 Jan; 113():104140. PubMed ID: 33080564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A theoretical analysis of long-term bisphosphonate effects on trabecular bone volume and microdamage.
    Nyman JS; Yeh OC; Hazelwood SJ; Martin RB
    Bone; 2004 Jul; 35(1):296-305. PubMed ID: 15207770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.
    Popp AW; Zysset PK; Lippuner K
    Osteoporos Int; 2016 May; 27(5):1917-21. PubMed ID: 26694598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar relationship between the time course of bone mineral density improvement and vertebral fracture risk reduction with denosumab treatment in postmenopausal osteoporosis and prostate cancer patients on androgen deprivation therapy.
    Pérez Ruixo JJ; Zheng J; Mandema JW
    J Clin Pharmacol; 2014 May; 54(5):503-12. PubMed ID: 24214315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data.
    Zheng J; van Schaick E; Wu LS; Jacqmin P; Perez Ruixo JJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):333-47. PubMed ID: 26123919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment.
    Petranova T; Sheytanov I; Monov S; Nestorova R; Rashkov R
    Biotechnol Biotechnol Equip; 2014 Nov; 28(6):1127-1137. PubMed ID: 26019600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline Characteristics and Changes in Bone Mineral Density T-Scores of Bulgarian Women with Postmenopausal Osteoporosis Receiving Denosumab in Routine Clinical Practice.
    Boyanov M; Shinkov A; Psachoulia E; Intorcia M; Petkova R
    Drugs R D; 2017 Mar; 17(1):125-132. PubMed ID: 27988913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of cancellous bone quality in severe osteoarthrosis: bone mineral density, mechanics, and microdamage.
    Fazzalari NL; Forwood MR; Smith K; Manthey BA; Herreen P
    Bone; 1998 Apr; 22(4):381-8. PubMed ID: 9556139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.
    Bilezikian JP; Lin CJF; Brown JP; Wang AT; Yin X; Ebeling PR; Fahrleitner-Pammer A; Franek E; Gilchrist N; Miller PD; Simon JA; Valter I; Zerbini CAF; Libanati C; Chines A
    Osteoporos Int; 2019 Sep; 30(9):1855-1864. PubMed ID: 31201481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoporosis: New-Generation Drugs.
    Resch H
    Breast Care (Basel); 2010; 5(5):313-319. PubMed ID: 21779213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice].
    Skripnikova IA; Kosmatova OV; Abirova ES; Novikov VE; Murashko LM
    Ter Arkh; 2017; 89(12. Vyp. 2):190-196. PubMed ID: 29488480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients.
    Suzuki T; Nakamura Y; Kato H
    Nutrients; 2017 Aug; 9(8):. PubMed ID: 28805705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches.
    Langdahl B
    Bone; 2020 Oct; 139():115516. PubMed ID: 32622871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
    Genant HK; Engelke K; Hanley DA; Brown JP; Omizo M; Bone HG; Kivitz AJ; Fuerst T; Wang H; Austin M; Libanati C
    Bone; 2010 Jul; 47(1):131-9. PubMed ID: 20399288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
    Mok CC; Ho LY; Ma KM
    Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.